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Introduction 
 The peroxisome proliferator activated 
receptors (PPARs) are members of the nuclear 
hormone receptor gene superfamily of ligand-
activated transcription factors [Issemann and 
Green, 1990]. So far, three distinct subtypes of 
PPARs have been identified, PPARα, PPARγ 
and PPARβ/δ, with each subtype encoded by 
a separate gene and has a specific tissue 
distribution [Issemann and Green, 1990; 
Braissant et al, 1996]. The PPARα, the first 
isoform to be identified, is expressed mainly 
in tissues that have high ratio of fatty acid 
oxidation such as liver, heart and kidney 
[Issemann and Green, 1990; Braissant et al., 
1996]. PPARα has attracted considerable 
attention since it was demonstrated to be 
regulators of lipoprotein metabolism [Staels et 
al., 1998], vascular inflammation [Chinetti et 
al., 2000], atherosclerosis [Chinetti et al., 
2000; Pineda-Torra et al, 2002] and 
carcinogenesis [Neve et al., 2000; Collett et 
al., 2000]. Moreover, recent studies suggested 
important roles for PPARα in skin wound 
healing, and epidermal maturation and repair 
[Wahli, 2002].  
 In order to understand the structure and 
molecular mechanisms governing hPPARα 
regulation, we carried out experiments to 
identify and characterise the 5’-untranslated 
region (UTR) and promoter regions of the 
hPPARα gene. In this study, we managed to 
identify six differentially spliced variants in 
the 5’-untranslated region (UTR) of human 
PPARα gene, due to four different promoter 
usages and alternative splicing [Chew et al., 
2003]. Since promoter A has been 
characterised [Pineda-Torra et al., 2002], three 
other promoters designated as promoter B, C 
and D were cloned, sequenced and their 
promoter activities analysed. By carrying out 
transient transfection analysis in human 
hepatocarcinoma HepG2 cells, we proved 
these three promoters are functional 
promoters, capable of inducing the basal 
luciferase gene expression, with promoter B 
being the most potent and strongest promoter 
of the three promoters. 
 
Materials and Methods 
 
Isolation of total cellular RNA 
 Total cellular RNA was isolated from the 
human hepatoma HepG2 cell line using Tri-
Reagent LS (Molecular Research Center) 
according to the manufacturer’s instruction. 
The concentration of each total cellular RNA 
was then quantified using GeneQuant 
(Amersham Pharmacia Biotech).  
 
Rapid amplification of cDNA ends (5’RLM-
RACE) and sequencing of RACE products 
 5’RLM-RACE was performed on 5 µg 
total RNA using the GeneRacer™ Kit 
(Invitrogen® Life Technologies) according to 
the manufacturer’s instruction. The first strand 
cDNA was generated using primers supplied 
by the manufacturer and subjected to two PCR 
reactions. Specifically, the synthesised cDNA 
was used as the template in the amplification 
process using the internal gene-specific primer 
GSP1 (5’-GCAGG 
AACTCTTCAGATAACGG-3’), located at 
the 5’ end hPPARα exon 3 and the 
GeneRacer™ 5’ Primer. PCR cycling 
parameters were as follows: initial 
denaturation at 94°C for 3 min followed by 30 
cycles of 1 min at 94°C, 1 min at 65°C, 1 min 
at 60°C, and 1 min at 72°C with a final 
elongation at 72°C for 10 min. The primary 
PCR mix was then subjected to a nested PCR 
under the same conditions with the 
GeneRacer™ 5’ Nested Primer and GSP2 (5’-
GCAGAGTGGGCTTTCCGTGT-3’) 
designed immediately upstream of GSP1. 
Oligonucleotides GeneRacer™ 5’ Primer and 
GeneRacer™ 5’ Nested Primer were provided 
in the GeneRacer™ Kit. The PCR products 
were size fractionated on 1.5% (w/v) agarose 
gel and selected bands were then gel purified 
using QIAquick gel extraction kit (QIAGEN). 
The purified bands were directly ligated into 
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pGEM-T Easy vector (Promega) and 
transformed into JM109. Recombinant 
plasmids were then isolated and purified for 
DNA sequencing using Plasmid Midi Kit 
(QIAGEN). Sequencing reactions were 
carried out using the ABI PRISM® BigDyeTM 
Terminator Cycle Sequencing Ready Reaction 
Kit (PE Applied Biosystem). 
 
Cloning and construction of reporter-
plasmids 
 The promoter regions were amplified from 
human genomic DNA as template with 
Platinum® Pfx DNA polymerase (Invitrogen® 
Life Technologies) to minimise PCR 
generated mutations. These products were 
then used as template for generating promoter 
fragments which represent different regions of 
these three promoters. The promoters’ 
fragments with different sizes were amplified 
from the cloned promoter as template using 
primers containing XhoI and HindIII to 
facilitate the cloning into the pGL3-Basic 
vector (Promega) in the correct orientation. 
For promoter B, reporter-promoter plasmids, 
pGL3alphB1 (carrying regions -341/+34), 
pGL3alphB2 (-765/+34) and pGL3alphB3 (-
1147/+34), were constructed. For promoter C, 
reporter-promoter constructs were cloned and 
named pGL3alphC1 (carrying regions -
413/+41), pGL3alphC2 (-967/+41), 
pGL3alphC3 (-1364/+41), while in promoter 
D, reporter-promoter plasmids designated 
pGL3alphD1 (-395/+28), pGL3alphD2 (-
672/+28) and pGL3alphD3 (-934/+28) were 
constructed. 
 
Cell culture and transient transfection assays    
 Human hepatoma HepG2 cell line were 
grown in Eagle’s Minimum essential medium 
with Earle’s BSS medium (Gibco) 
supplemented with 10% (v/v) fetal bovine 
serum, 2mM L-glutamine, 100 U/ml penicillin 
and 100 µg/ml streptomycin (Hyclone). The 
cultures were maintained at 37oC in a 
humidified atmosphere containing 5% (v/v) 
CO2 in air. The cells were transfected with 
individual promoter fragment, together with 
pRL-TK containing Renilla luciferase 
(Promega) which served as internal control, 
using Lipofectin transfection reagent 
(Invitrogen® Life Technologies) according to 
the manufacturer’s instructions for 36 hrs. The 
luciferase activities in the cell extracts were 
then determined using the Dual-Luciferase 
Reporter Assay System (Promega). The firefly 
luciferase activity was normalised to the 
Renilla luciferase activity, with each 
transfection being carried out in triplicate and 
measurements were repeated at least twice.  
 
Results and Discussion 
 
Identification of Alternatively Spliced 
Variants of the 5’ UTR of hPPARα gene 
Using RLM-RACE PCR approach, six 
RACE-PCR products of different sizes 
(100bp, 200bp, 230bp, 300bp, 330bp and 
600bp) were successfully amplified (figure 
not shown). Sequencing analysis showed that 
the 3’ end of all RACE-PCR products shared 
100% identity with the 5’ end of Exon 3 of 
human PPARα gene, where the gene-specific 
primers were designed, indicating that all 
RACE-PCR products were specific and 
represent the 5’-UTR of the human PPARα. 
Interestingly, sequence analysis amongst the 
six RACE-PCR products revealed different 
combination of exons which strongly indicates 
the existence of 6 differentially spliced 
variants in the 5’-UTR of the hPPARα gene, 
designated as hPPARα1, hPPARα2, 
hPPARα3, hPPARα4, hPPARα5 and 
hPPARα6 (Figure 1A) [Chew et al., 2003].  
 In addition to these six alternatively 
spliced variants, we have also successfully 
identified three new novel exons of the human 
PPARα gene, designated Exon A, Exon B and 
Exon 2b (Figure 1B) [Chew et al., 2003]. 
The presence of alternatively spliced 
variants in human PPARα mRNA is a 
common phenomenon amongst PPAR 
isoforms. For example, four variants resulting 
from four different promoters usages and 
alternative splicing at the 5’-UTRs have been 
identified in human PPARγ mRNA [Fajas et 
al., 1997, Fajas et al., 1998, Sundvold and 
Lien, 2001], while seven alternatively spliced 
variants were detected in monkey PPARγ 
mRNA [Zhou et al., 2002]. In addition, four 
differentially spliced variants induced by four 
differential promoter usages were also 
detected in mouse PPARβ mRNA [Larsen et 
al., 2002]. Meanwhile, in porcine PPARα 
mRNA, two alternatively spliced mRNA were 
found in the coding region of PPARα 
[Sundvold et al., 2001].  
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FIGURE 1  (A) The six alternatively spliced variants identified from this study. Alternative splicing 
mechanisms and different promoters usage give rise to variants with unique combinations of exons. (B) 
Schematic representation of the 5’-UTR of hPPARα gene. The new exons identified are indicated as shaded 
boxes. Numbers in bold and in boxes represents the sizes of the introns which span the exons. Arrows 
indicate the presence of promoter in front of Exon A, Exon B, Exon 2a and Exon 3. 
 
Determination of transcriptional start sites 
RLM-RACE method allows only full 
length 5’-capped transcripts to be amplified 
via the elimination of truncated mRNA, 
thereby rendering it a safe, reliable and 
accurate method for mapping of the 5’ ends of 
transcripts and transcriptional start sites of 
genes [Maruyama et al., 1994, Volloch et al., 
1994]. The transcriptional start sites of Exon 3 
and Exon 2a were situated 31 bp and 124 bp 
upstream of the ATG initiation start codon in 
the processed mRNA, respectively, while 
exons A has two different transcriptional start 
sites, each individually marks the start site 
variants hPPARα3 and hPPARα5. The 
transcriptional start site of hPPARα3 and 
hPPARα5 are situated 172 bp and 264 bp 
upstream of the ATG initiation start codon, 
respectively; with the hPPARα5 
transcriptional start site located 8 nucleotides 
upstream of the transcriptional start site of 
variant PPARα3 in Exon A. Meanwhile, Exon 
B also has two transcriptional start sites 
(variant PPARα4 and variant PPARα6) 
mapped to the positions 251 bp and 540 bp 
upstream of their respective ATG start codon. 
The transcriptional start site for PPARα4 is 48 
bp upstream of the transcriptional start site in 
PPARα6 [Chew et al., 2003].     
 Multiple transcriptional start sites within 
the same promoter region are in fact a 
common phenomenon and frequently 
observed PPAR family, i.e. in the mouse 
PPARα and PPARβ gene [Larsen et al., 2002, 
Gearing et al., 1994].  
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Cloning and analysis of the promoter regions 
B, C and D 
 We determined the transcriptional start 
sites for each variant of the human PPARα 
gene, which suggested the presence of four 
promoters responsible for transcribing these 
variants. Since promoter A was identified and 
characterised (Pineda-Torra et al., 2002), 
promoters B, C and D were chosen to be 
further characterised. Direct PCR 
amplifications using human genomic DNA as 
template and gene-specific primers were 
carried out to amplify these putative promoter 
regions. Products with sizes of 1.2 kb 
(promoter B), 1.5 kb (promoter C) and 1.0 kb 
(promoter D) were successfully amplified.  
 A computer search of the putative 
promoter regions using the Matisnspector 
programme in TRANSFAC database 
(http://transfac.gbf.de 
/TRANSFAC/index.html) revealed the 
existence of multiple potential binding sites 
for transcription factors that may regulate the 
expression of the human PPARα gene. 
Binding sites for transcription factors such as 
Oct-1, AP-1, Sp1, C/EBP, STAT, GATA-1, 
GATA-2, HNF-3β and RORα1 were 
identified within the promoters B, C and D 
regions of human PPARα gene (figures not 
shown). 
 
Characterisation and analysis of promoters 
B, C and D activities 
The relative strength of the different 
promoters and different fragments of the 
promoters was compared by transient 
transfection in Hep3B and HepG2 cells, using 
various fragments of promoters’ sequences. 
Fragments containing regions -341/+34 
(pGL3alphB1), -765/+34 (pGL3alphB2) and -
1147/+34 (pGL3alphB3) of promoter B, 
fragments bearing the regions -413/+41 
(pGL3alphC1), -967/+41 (pGL3alphC2) and  
-1364/+41 (pGL3alphC3) of promoter C and 
fragments -395/+28 (pGL3alphD1), -672/+28 
(pGL3alphD2) and -934/+28 (pGL3alphD3) 
of promoter D were cotransfected into the 
cells with pRL-TK plasmid which served as 
an internal control for transfection efficiency. 
Results obtained from this study proved that 
all three promoters B, C and D are functional 
promoters capable of driving the basal 
transcription of the luciferase gene.  
 Promoter activities for promoter B were 
the highest in HepG2 cells compared to 
promoter C and D, thereby indicating that 
promoter B is the highest promoter of the 
three, followed by promoter D being a 
stronger promoter than promoter C (Figure 2).  
Overall, the smallest promoter fragments 
of the three promoters, pGL3alphB1 (-
341/+34), pGL3alphC1 (-413/+41) and 
pGL3alphD1 (-395/+28), proved to have the 
strongest activity compared to their respective 
fragments in HepG2 cells (Figure 2). This 
could indicate the absence of elements 
conferring transcriptional repression upstream 
of the start sites, or alternatively, the presence 
of an element enhancing transcription between 
positions -341 to +34 of promoter B, positions 
-413 to +41 of promoter C, and positions -395 
to +28 of promoter D, or a combination of 
both.  
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FIGURE 2  Analysis of promoters B, C and D activities using transient transfection assays. The 
promoter fragments of promoters B, C and D were fused into pGL3 basic vector and co-transfected with 
pRL-TK into HepG2. Values (mean ± SD) represent firefly luciferase activity normalised to a Renilla 
luciferase activity which served as internal control. Luciferase activities are shown relative to the activity of 
the pGL3 basic vector. 
 
 
Conclusions 
Six variants, named hPPARα1, hPPARα2, 
hPPARα3, hPPARα4, hPPARα5 and 
hPPARα6, were successfully identified at the 
5’-UTR of human PPARα mRNA as a result 
of alternatively splicing and the use of four 
different promoters. Each of the 
transcriptional start sites of the variant was 
determined and mapped, leading to the 
discovery of four promoters in the human 
PPARα gene which are responsible for 
transcribing these alternatively spliced 
variants. In addition, three new novel exons 
designated Exon A, Exon B and Exon 2b were 
identified in this study. Three new novel 
human PPARα promoters were also cloned 
and characterised. Demonstrated by transient 
transfection assay, these putative promoters B, 
C and D were all proven to be functional 
promoters, with promoter B being the 
strongest of the three promoters. 
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